MoneyWorks4Me

Lupin gets USFDA’s tentative nod for Empagliflozin, Linagliptin Tablets

24 Jul 2020 Evaluate

Lupin has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (RLD: Glyxambi) had an annual sales of approximately $242 million in the U.S. (IQVIA MAT Mar 2020).

Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2111.00 -24.00 (-1.12%)
04-Sep-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.00
Dr. Reddys Labs. 1154.00
Cipla 1385.00
Lupin 2111.00
Zydus Lifesciences 1121.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: